0001869105 2026-09-01 2026-09-01 0001869105 dei:BusinessContactMember 2026-09-01 2026-09-01 POS AM CA CA true 0001869105 BRIDGEBIO ONCOLOGY THERAPEUTICS, INC. DE 39-3690783 256 E. Grand Avenue Suite 104 South San Francisco 94080 650 405-4770 Pedro J. Beltran 256 E. Grand Avenue Suite 104 South San Francisco 94080 650 405-4770 Non-accelerated Filer true true false On August 29, 2025, BridgeBio Oncology Therapeutics, Inc. (the “Company”) filed a registration statement with the U.S. Securities and Exchange Commission (the “SEC”) on Form S-1 (File No. 333-289940) (the “Registration Statement”), which was initially declared effective by the SEC on September 10, 2025. This Post-Effective Amendment No. 2 to Form S-1 on Form S-3 (this “Post-Effective Amendment”) to the Registration Statement is being filed to convert the Registration Statement into a registration statement on Form S-3. The information included in this filing amends the Registration Statement and the prospectus contained therein. No additional securities are being registered under this Post-Effective Amendment. All applicable registration fees were paid at the time of the original filing of the Registration Statement on August 29, 2025.